Sign-up for our newsletter
Pilot & Feasibility
Protocols & Methods
Reagents & Resources
Tissues & Samples
IMPC / KOMP Data
Pilot & Feasibility
Brigham and Womens Hospital
Modeling Diabetic Kidney Fibrosis with Kidney Organoids derived from Human Pluripotent Stem Cells
We have established a highly efficient and specific protocol for generation of SIX2+ nephron progenitor cells (NPCs) and kidney organoids consisting of podocytes, proximal tubules, loops of Henle, distal tubules, and connecting tubules/collecting ducts with interstitial cells, from human pluripotent stem cells (hPSCs). This novel technology represents additional systems for studies of kidney diseases and regeneration. Chronic kidney disease (CKD) is a worldwide health care problem and diabetic kidney disease is the major cause for CKD. To develop targeted therapies for CKD caused by diabetes, it is vital to understand underlining molecular mechanisms. Kidney organoids derived from hPSCs can be a novel tool to study mechanisms of fibrosis in human tissues; however, little is known about modeling kidney fibrosis with organoids. Tubulointerstitial crosstalk contributes to development of kidney fibrosis, and damage to tubular cells leads to profibrotic phenotypes of tubules characterized by dedifferentiation, cell cycle arrest, and profibrotic cytokine production. The origin of myofibroblasts includes local resident fibroblasts, bone marrow, and pericytes. The human stem cell-derived organoids consist of multi-cellular compartments including nephron epithelial cells, vascular cells, and interstitial stromal cells including fibroblasts and pericytes in 3-dimensional structures, and our previous work demonstrated cisplatin-induced injury to LTL+ proximal tubules, but not to podocytes or interstitial cells. These facts led us to hypothesize that kidney organoids can be used to study tubulointerstitial cross talk implicated in kidney fibrosis, with nephrotoxicants specific to proximal tubules (Aim 1). In addition, our preliminary experiment demonstrated upregulation of CTGF, a profibrotic cytokine, in organoids with high glucose treatment, leading us to hypothesize that high glucose treatment exacerbates the profibrotic phenotype of tubular epithelial cells when exposed to nephrotoxicants (Aim 2). With this pilot study, we anticipate that the human stem cell-derived organoids would provide a novel platform to study mechanisms of kidney fibrosis in human cells, expecting to find clues to understand molecular mechanisms of how diabetes mellitus exacerbates kidney fibrosis through profibrotic induction in tubular cells.
Drag a column header and drop it here to group by that column
Modeling Diabetic Kidney Fibrosis with Kidney Organoids derived from Human Pluripotent Stem Cells (Morizane, Ryuji)
View Progress Report Document
No uploaded documents found.
No publications found.
No uploaded documents found.
No protocols found.
The DiaComp Steering Committee is the governing body of the consortium. The principle function of this committee is to guide the scientific direction of the consortium. This is accomplished by creating various subcommittees necessary to advance the scientific goals and providing guidance to the broader complications research community. Policies for the consortium are developed through consultation with the
External Evaluation Committee
The DiaComp Nephropathy Committee has the principal function of furthering the mission of the consortium with regard to diabetic kidney disease.
Curation Flag Information
New comment to be added:
No experiments found.
No strains found.
No models found.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an external advisor to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!